- Home >
- Publications >
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Authors
A. Bardia, S.M. Tolaney, K. Punie, D. Loirat, M. Oliveira, K. Kalinsky, A. Zelnak, P. Aftimos, F. Dalenc, S. Sardesai, E. Hamilton, P. Sharma, S. Recalde, E.C. Gil, T. Traina, J. O’Shaughnessy, J. Cortes, M. Tsai, L. Vahdat, V. Diéras, L.A. Carey, H.S. Rugo, D.M. Goldenberg, Q. Hong, M. Olivo, L.M. Itri, S.A. Hurvitz